Natus Medical Incorporated (NASDAQ:BABY) has been given a consensus recommendation of “Hold” by the seven research firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $48.00.

Several research firms have weighed in on BABY. BidaskClub downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th.

In other Natus Medical news, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $35.17, for a total transaction of $154,748.00. Following the completion of the sale, the director now directly owns 50,850 shares in the company, valued at approximately $1,788,394.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William M. Moore sold 3,000 shares of Natus Medical stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $34.10, for a total transaction of $102,300.00. Following the sale, the director now owns 30,410 shares of the company’s stock, valued at $1,036,981. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in BABY. BlackRock Inc. lifted its stake in Natus Medical by 137,510.8% during the 1st quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock valued at $161,874,000 after acquiring an additional 4,121,198 shares during the period. Columbia Wanger Asset Management LLC lifted its stake in Natus Medical by 243.6% during the 1st quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock valued at $79,686,000 after acquiring an additional 1,439,382 shares during the period. Wellington Management Group LLP lifted its stake in Natus Medical by 105.7% during the 1st quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock valued at $70,457,000 after acquiring an additional 922,268 shares during the period. Koch Industries Inc. lifted its stake in Natus Medical by 7,423.5% during the 2nd quarter. Koch Industries Inc. now owns 462,472 shares of the medical equipment provider’s stock valued at $450,000 after acquiring an additional 456,325 shares during the period. Finally, Epoch Investment Partners Inc. lifted its stake in Natus Medical by 68.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,110,932 shares of the medical equipment provider’s stock valued at $43,604,000 after acquiring an additional 450,698 shares during the period. Institutional investors and hedge funds own 92.65% of the company’s stock.

Shares of Natus Medical (NASDAQ:BABY) traded down 1.40% on Friday, reaching $35.10. 310,860 shares of the company were exchanged. Natus Medical has a 52 week low of $31.65 and a 52 week high of $44.39. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 60.83 and a beta of 0.96. The firm’s 50 day moving average price is $33.95 and its 200 day moving average price is $36.10.

Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.01. The company had revenue of $122.20 million for the quarter, compared to the consensus estimate of $121.99 million. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. Natus Medical’s revenue was up 27.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.39 EPS. Equities research analysts anticipate that Natus Medical will post $1.70 EPS for the current year.

WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/16/natus-medical-incorporated-baby-receives-average-recommendation-of-hold-from-analysts.html.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.